[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627792":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":26,"responsibleParty":37,"collaborators":26,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":43,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":26,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":66,"whyStopped":26,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":26},{"fullName":5,"class":6},"Hayat Abad Medical Complex, Peshawar","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Topical Calcipotriol","EXPERIMENTAL","Participants in this arm received topical calcipotriol applied to affected scalp areas for 12 weeks. Treatment response was assessed at 4-week intervals using the Severity of Alopecia Tool (SALT) score",[13],"Drug: Calcipotriol",{"label":15,"type":16,"description":17,"interventionNames":18},"Intralesional Corticosteroids","ACTIVE_COMPARATOR","Participants in this arm received intralesional corticosteroid injections administered into alopecia lesions for 12 weeks. Clinical response was evaluated at 4-week intervals using the Severity of Alopecia Tool (SALT) score.",[19],"Drug: Triamcinolone Acetonide",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Calcipotriol","Topical calcipotriol 0.005% ointment was applied to affected scalp areas twice daily for 12 weeks. Participants were instructed to apply a thin layer over alopecia patches and gently massage into the scalp. Treatment response was evaluated at weeks 4, 8, and 12 using the Severity of Alopecia Tool (SALT) score. Adverse effects were monitored throughout the study period",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Triamcinolone Acetonide","Triamcinolone acetonide was administered as intralesional injections at a concentration of 5 mg\u002FmL into alopecia patches at 4-week intervals for 12 weeks. Injections were delivered intradermally using a fine-gauge needle, with dose distributed across affected lesions according to lesion size. Clinical response was assessed at weeks 4, 8, and 12 using the Severity of Alopecia Tool (SALT) score. Participants were monitored for local adverse effects such as skin atrophy and telangiectasia.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Huma Gul Huma Gul, FCPS","CONTACT","03319061411","gul.gullaii.1995@gmail.com",{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Huma Gul","PGR","100627792","phase-4-comparison-of-topical-calcipotriol-and-intralesional-steroids-in-alopecia-areata-100627792",false,"NCT07453238","Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata","Comparison of Topical Calcipotriol Versus Intralesional Corticosteroids in the Treatment of Alopecia Areata: A Randomized Controlled Trial","CALISTA-AA","Inclusion Criteria:\n\n* Adults aged 18 to 50 years\n* Clinically diagnosed patchy alopecia areata\n* Scalp involvement of less than 50% (SALT score \\\u003C50%)\n* No topical or systemic treatment for alopecia areata within the previous 3 months\n* Willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Diffuse alopecia areata or scarring alopecia\n* Presence of other autoimmune diseases or significant systemic illness\n* Known hypersensitivity to calcipotriol or corticosteroids\n* Pregnant or lactating women\n* Current use of immunosuppressive therapy\n* Unwillingness to participate or provide informed consent","ALL","18 Years","50 Years",{"count":53,"type":54},60,"ESTIMATED","INTERVENTIONAL",[57],"PHASE4","This randomized controlled trial compares the effectiveness of topical calcipotriol and intralesional corticosteroids in the treatment of alopecia areata. Alopecia areata is an autoimmune condition that causes non-scarring hair loss and can significantly affect quality of life. Intralesional corticosteroids are commonly used as first-line therapy; however, response rates vary and treatment may be associated with discomfort and local adverse effects.\n\nSixty adult patients with patchy alopecia areata involving less than 50% of the scalp were randomly assigned to receive either topical calcipotriol or intralesional corticosteroid injections for 12 weeks. Participants were evaluated at four-week intervals. Treatment response was assessed using the Severity of Alopecia Tool (SALT) score and percentage improvement from baseline.\n\nThe primary objective is to compare reduction in SALT score between the two treatment groups. Secondary outcomes include overall treatment efficacy and safety. The findings aim to determine whether topical calcipotriol provides superior or comparable clinical benefit to intralesional corticosteroids in patients with alopecia areata.",[60],"Alopecia Areata",[60,9,15,62,63,64,65],"Randomized Controlled Trial","Hair Regrowth","Vitamin D Analog","Patchy Alopecia","NOT_YET_RECRUITING","2026-03-02",{"date":69,"type":70},"2026-03-05","ACTUAL",{"date":72,"type":54},"2026-04-01",{"date":74,"type":54},"2026-10-01",{"name":5,"class":6}]